Queue Raises $12.6M Seed Round to Commercialize Autonomous Robotic Pharmacy

The pharmacy counter has become one of the strangest places in modern healthcare. We have built billion-dollar drug discovery engines, AI systems that can identify disease patterns in seconds, and robots capable of assembling vehicles with microscopic precision. Then someone still waits while a prescription gets counted into a bottle. Queue believes that contradiction is the opportunity.

The Palo Alto startup emerged from stealth after raising $12.6M in seed funding led by AlleyCorp, with participation from House Capital, Ubiquity Ventures, Grep Ventures, Banter Capital, and returning investor Riot Ventures. The financing brings Queue's total funding to $18.6M and supports commercialization of what the company describes as the world's first fully autonomous robotic pharmacy.

The founders are betting on something larger than pharmacy automation. They are betting that healthcare's next efficiency gains will come from rebuilding operational infrastructure instead of asking already overextended clinicians to simply work harder.

What Happened

Queue, founded by CEO Nick Desai and CTO Josh Liu, is developing an autonomous robotic pharmacy platform designed to automate prescription dispensing from sealed wholesale medication bottles through final patient pickup. Unlike many pharmacy automation systems that still depend on significant human intervention, Queue's approach focuses on automating the mechanical workflow that has remained largely unchanged for decades.

The system uses computer vision to verify medications, tracks chain of custody throughout the dispensing process, and allows patients to retrieve prescriptions using QR-code verification. According to the company, the platform supports roughly 250 of the most commonly prescribed medications in the United States and can fill a 60-pill vial in about 30 seconds. Those are not just engineering statistics. They are early indicators of where healthcare infrastructure is beginning to evolve.

The funding round was led by AlleyCorp, with participation from House Capital, Ubiquity Ventures, Grep Ventures, Banter Capital, and returning investor Riot Ventures, which previously led Queue's pre-seed financing. Queue has also deployed a working prototype with an undisclosed national pharmacy customer and is targeting broader commercial rollout in early 2027.

For Desai and Liu, this is not a first trip through difficult markets. Desai previously built Heal, one of digital healthcare's most recognizable home-care platforms, while Liu brings engineering leadership experience from Tesla, Waymo, and Zipline. Investors often say they back founders rather than ideas. In this case, they are backing both.

Why This Matters

The easiest way to misunderstand Queue is to think it is building robots to replace pharmacists. The more accurate interpretation is that Queue is trying to replace repetitive mechanical work that keeps pharmacists away from higher-value patient care.

Healthcare continues to face persistent labor shortages, rising operating costs, increasing prescription demand, and growing pressure to improve access across underserved communities. Those forces create a difficult equation for pharmacies that already operate on narrow margins. If repetitive dispensing tasks become software and robotics problems instead of labor problems, pharmacists gain more time for medication counseling, clinical review, patient education, and interventions that actually require human expertise.

That distinction matters because healthcare does not have a technology shortage. It has an allocation problem. The industry's highest-value professionals frequently spend time performing its lowest-value repetitive tasks, and Queue's technology attempts to rebalance that equation. Whether the company succeeds commercially remains to be seen, but it is attacking a structural inefficiency rather than chasing another incremental software feature.

Market Context

Queue is entering the market as pharmacy operators face several converging pressures. Prescription volumes continue to rise alongside an aging population, labor shortages remain a persistent challenge across pharmacy operations, and many communities have experienced pharmacy closures that increase travel times and reduce healthcare access for patients who already face barriers to care.

Those forces create demand for automation that extends beyond simple cost reduction. Automation has become an operational resilience strategy because healthcare organizations increasingly evaluate technology not only by how much money it saves, but by how consistently it allows essential services to operate despite staffing volatility.

That dynamic helps explain why investors continue allocating capital toward healthcare robotics, AI-enabled infrastructure, and intelligent operational systems. Queue sits directly at the intersection of all three categories. Rather than building another digital health application competing for consumer attention, the company is attempting to modernize physical healthcare infrastructure that millions of patients interact with every year. Infrastructure rarely generates viral headlines, but it often generates durable businesses.

Competitive Landscape

Healthcare automation is becoming increasingly crowded, but most companies concentrate on software workflows, clinical documentation, AI assistants, scheduling, or administrative efficiency. Queue focuses on physical execution, which creates both opportunity and complexity.

Building enterprise software is difficult. Building reliable robotics for regulated healthcare environments is considerably harder. Hardware, software, computer vision, operational reliability, pharmacy compliance, and healthcare logistics all have to work together with minimal room for failure. That challenge also creates a competitive barrier.

The backgrounds of Queue's leadership team reflect that reality. Desai contributes healthcare operating experience, while Liu brings robotics and hardware expertise developed across Tesla, Waymo, and Zipline, organizations where precision engineering is a prerequisite rather than a marketing slogan. Investors appear to recognize that combination. AlleyCorp has developed a reputation for backing ambitious healthcare and deep technology companies, while Riot Ventures' continued participation signals confidence beyond an initial seed-stage thesis. Repeat investors rarely double down because a press release sounded impressive. They do it because execution continues matching expectations.

What This Signals

Queue's financing reflects a broader shift occurring throughout venture capital. Capital is increasingly flowing toward companies solving infrastructure problems that are difficult, expensive, and operationally meaningful.

The startup ecosystem spent years optimizing convenience for consumers. The next wave appears increasingly focused on rebuilding the systems underneath those consumer experiences. Healthcare offers one of the largest opportunities because many of its operational workflows still reflect assumptions from decades ago, despite advances in AI, robotics, cloud computing, and machine learning.

Queue is not simply digitizing an existing workflow. It is questioning whether the workflow should exist in its current form at all, and that is usually where the largest opportunities emerge.

The Bigger Industry Shift

Every generation of technology believes it will transform healthcare. Most discover that healthcare changes more slowly than expected because complexity always wins the first round. Queue represents a different philosophy.

Instead of asking hospitals, pharmacies, clinicians, and patients to radically change behavior, Queue attempts to redesign the operational machinery working behind the scenes. If successful, patients experience faster prescription fulfillment, pharmacists spend more time practicing pharmacy instead of counting pills, and pharmacy operators gain greater efficiency without asking employees to absorb ever-growing workloads.

That combination explains why this funding announcement deserves attention beyond another venture capital headline. The story is not simply that Queue raised $12.6M. The story is that investors increasingly believe healthcare's next chapter will be written by companies modernizing invisible infrastructure rather than adding another app to an already crowded home screen. Sometimes the biggest innovation is not creating something entirely new. It is finally fixing the part of the system everyone assumed had to stay broken.